Squamous cell neoplasm

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This phase 2 trial tests whether the combination of pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy) can shrink tumors in people with advanced anal squamous cell cancer that cannot be removed by surgery or has spread to other organs. Participants must have alr…

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This early-phase trial tests whether a new drug (ATRN-119) combined with a single, precise dose of radiation to the neck can safely and effectively treat early-stage HPV-positive throat cancer before surgery. About 35 participants will take the drug daily for 10 days and receive …

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This large Phase 3 trial is testing a new drug called APG-157, given as a pastille that dissolves in the mouth, for people with advanced head and neck cancer. The study will see if adding APG-157 before and after standard treatments (surgery or chemoradiation) helps keep the canc…

This trial tests whether combining an immune-boosting cream (imiquimod) with a low dose of an immunotherapy drug (nivolumab) can shrink vulvar squamous cell carcinoma tumors before surgery. About 50 women with resectable, early-to-moderate stage vulvar cancer will receive the dru…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This study tests whether a short course of radiation followed by the immunotherapy drug tislelizumab plus chemotherapy can improve outcomes for people with a type of esophageal cancer that can be surgically removed. About 50 participants will receive either a low or high dose of …

This phase II trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy that attacks cancer cells with a specific protein) and Pucotenlimab (an immunotherapy that boosts the immune system)—in men with advanced penile cancer that is hard to treat with surgery al…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This trial tests whether giving trilaciclib before chemotherapy and immunotherapy can protect bone marrow in people with advanced head and neck cancer. The goal is to reduce dangerous drops in blood cell counts, allowing patients to receive their full chemo doses on schedule. Abo…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This study tests a new approach for treating high-grade cervical precancer (HSIL) using a cream called HAL that is activated by a special light, instead of standard surgery. About 230 women will be randomly assigned to receive either the light therapy or surgery. The main goal is…

This phase 2 trial tests whether adding MRG003 (a targeted drug) to toripalimab (an immunotherapy) before surgery can shrink tumors more than toripalimab alone in people with PD-L1-positive, locally advanced head and neck cancer. Participants receive two cycles of either the comb…

This phase 2 trial tests a drug called tisotumab vedotin in people with advanced squamous cell carcinoma of the vulva that has returned or spread. The drug is an antibody-drug conjugate designed to seek out and destroy cancer cells. The study aims to see how many participants' tu…

This clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This phase II trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to people with advanced hypopharyngeal cancer. The goal is to shrink tumors enough to improve surgical outcomes and possibly preserve the voice box. About 52 participants will receive thre…

This early-stage trial tests an injection called BBM-C101 in 60 women with high-grade cervical precancer linked to HPV16 or HPV18. The goal is to see if the drug is safe and can shrink or eliminate abnormal cells, potentially offering a non-surgical alternative. Participants rece…

This early-phase trial tests whether adding axelopran—a drug that blocks opioid effects on the immune system—can help pembrolizumab (an immunotherapy) work better in people with advanced head and neck cancer who take opioids for pain. About 18 participants will receive both drugs…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This study tests a new drug called SKB571 in 30 adults with head and neck cancer that has returned or spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for response and…

This study tests a new drug called samuraciclib added to standard chemotherapy for people with a specific type of advanced pancreatic cancer (basal-like). The goal is to find the safest dose and see if the combination helps shrink tumors or slow the cancer. About 67 adults with n…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This study tests whether matching drug combinations to a patient's tumor genetics can help when standard immunotherapy stops working. About 90 people with advanced esophageal cancer will get one of three treatment pairs based on their cancer's molecular profile. The goal is to se…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This early-phase trial tests whether specially engineered immune cells (NK cells) can safely treat high-risk precancerous spots in the mouth. The cells are injected directly into the lesions and are designed to target a protein called TROP2, while also resisting signals that norm…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This Phase 3 trial tests whether patients with esophageal cancer who respond well to initial drug therapy can safely avoid surgery and instead receive chemoradiotherapy to preserve their esophagus. Over 1,000 participants will be randomly assigned to either surgery or organ prese…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study is testing two remote programs—a chatbot app called QuitBot and a text messaging service—to help American Indian and Alaska Native adults quit smoking. About 772 participants will be randomly assigned to one of the programs. The goal is to see which approach works bett…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests whether a blood test that detects HPV DNA can help doctors choose the right treatment for people with HPV-positive oropharyngeal cancer. About 116 participants with stage I to III cancer will receive either the immunotherapy drug pembrolizumab (Keytruda) or stand…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This phase III trial will enroll 854 Hispanic adults who smoke and want to quit. Participants will use the iCanQuit smartphone app, which teaches skills to manage cravings and prevent relapse. Half will also receive nicotine replacement therapy (gum, patch, or lozenge) to ease wi…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This study tests a new treatment plan for people with HPV-positive oropharyngeal cancer (a type of throat cancer linked to HPV). The plan combines an immune-boosting drug (nogapendekin alfa inbakicept), a vaccine targeting HPV, chemotherapy, and a lower dose of radiation. The goa…

This phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—as a first treatment for advanced head and neck squamous cell carcinoma. It is for patients whose cancer has returned or spread and who cannot tolerate p…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study compares two smartphone apps designed to help people stop smoking. One app uses a therapy that focuses on mood and behavior, while the other uses standard quitting advice. About 1,800 adult smokers who want to quit in the next month will use one of the apps for 30 days…

This phase 2 trial tests whether adding intermittent hypoxic training (IHT) – short sessions of breathing low-oxygen air – to standard chemo-immunotherapy can improve outcomes for people with stage II-IIIA lung squamous cell carcinoma. About 60 participants will receive either st…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This study tests whether a self-applied cream (5-fluorouracil) after a heat procedure (thermal ablation) can clear HPV better than a placebo cream in 140 women with HIV in Kenya. Participants will use the cream every two weeks for 24 weeks and be followed for 48 weeks total. The …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study looks at the best way to treat people with p53-mutant oral dysplasia (abnormal cells in the mouth) and early-stage oral cancer. About 636 adults will be placed into three groups based on their diagnosis and receive either monitoring, surgery, or surgery plus neck disse…

This Phase 3 trial tests a new drug called HS-20093 against standard chemotherapy in 494 people with advanced esophageal cancer that has worsened after initial treatment. The goal is to see if HS-20093 helps people live longer and controls the tumor better. Participants will rece…

This study tests whether adding a new drug called retlirafusp alfa to standard chemotherapy before surgery can help shrink tumors in people with a type of esophageal cancer. About 33 adults with locally advanced esophageal squamous cell carcinoma will receive the combination trea…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This Phase 3 trial tests whether using a blood test that detects tumor DNA can guide who needs extra therapy after esophageal cancer surgery. Participants will either receive a combination of immunotherapy (tislelizumab), chemotherapy, and radiation, or be monitored without addit…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This study tests a combination of an experimental drug (ficerafusp alfa), an immunotherapy (pembrolizumab), and targeted radiation before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive these treatments over several w…

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase study tests a new cancer vaccine (EVM14) combined with an immunotherapy drug (ivonescimab) in 13 people with advanced squamous non-small cell lung cancer that has not been treated before. The main goals are to check safety and find the right dose, while also look…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This study tests whether giving two drugs (becotatug vedotin and pucotenlimab) before surgery can shrink tumors in people with recurrent head and neck cancer that has stopped responding to standard treatments. About 42 adults with EGFR-positive cancer will receive 3 cycles of the…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase II trial tests whether combining two drugs—pucotenlimab (an immunotherapy) and becotatug vedotin (a targeted chemotherapy)—given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. About 80 participants will receive eith…

This early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This study tests a drug called adebrelimab combined with chemotherapy before deciding on surgery for people with a certain type of esophageal cancer. About 200 participants will receive the treatment first. If the cancer disappears completely on scans, they will be randomly assig…

This early-phase study tests a new mRNA medicine (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard treatments. The medicine is injected directly into tumors to help the body fight cancer. The main goal is to check safety and find the ri…

This phase II trial tests a combination of an antibody-drug conjugate (a targeted cancer drug) and stereotactic body radiotherapy (precise, high-dose radiation) in 40 people with recurrent or metastatic salivary gland cancer. Participants first receive the drug; if their disease …

This study tests a new type of radiation called FLASH therapy, which delivers the entire dose in milliseconds instead of minutes. The goal is to see if it can treat skin cancers (squamous cell and basal cell carcinomas) just as well as standard radiation but with fewer side effec…

This phase 2 trial tests a combination of two drugs, XL-092 and pembrolizumab (Keytruda), given before surgery to people with a type of oral cancer that is HPV-negative and can be removed. The goal is to see if the drugs can shrink or eliminate the tumor before the operation. Abo…

This early-stage trial tests a topical ointment called ACU-D1 for HPV-related vulvar and perianal lesions in people with HIV. Nine participants will apply the cream twice daily for 4 weeks. The main goal is to find the safest dose and see if the treatment can boost immune markers…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This study compares two treatments for people with advanced head and neck cancer who cannot use the standard drug cisplatin. About 454 participants will receive either cetuximab (a targeted antibody) or a chemotherapy combo (carboplatin + paclitaxel) alongside precise radiation t…

This study tests whether adding a targeted chemoembolization procedure to standard immunotherapy can help people with stage IV lung squamous cell carcinoma live longer without their cancer growing. About 166 participants who have already responded to initial treatment will be ran…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This study tests whether a probiotic called EXE-346 can help treat anal high-grade squamous intraepithelial lesions (HSIL) and reduce persistent high-risk HPV infection in people living with HIV. The trial will enroll 90 participants who will take the probiotic or a placebo daily…

This study tests whether adding the drug benmelstobart to standard radiotherapy and nimotuzumab can help prevent head and neck cancer from coming back after surgery. About 386 patients with intermediate-risk features will be randomly assigned to one of two groups. The main goal i…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This phase 2 trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to a special type of radiation and standard chemotherapy can help people with advanced, bulky head and neck cancer live longer without the disease getting worse. The study will enroll 2…

This study tests whether giving radiation along with immunotherapy before surgery works better than immunotherapy alone for people with advanced head and neck cancer. About 36 adults with treatable but advanced cancer will be split into two groups. The goal is to see if the combi…

This study tests a new combination of drugs (BL-B01D1 plus tislelizumab, with or without chemotherapy) as a first treatment for people with advanced esophageal cancer that cannot be removed by surgery. About 90 participants will be randomly assigned to receive either the new comb…

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This phase 2 trial will test whether adding the experimental drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 49 participants will receive three cycles of the combination, then under…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This study tests whether giving two drugs together before surgery can shrink advanced mouth or throat cancers. The drugs are becotatug vedotin and pucotenlimab. About 26 people with stage III or IVa cancer will take part. The goal is to see if the cancer nearly or completely disa…

This phase 2 trial tests whether a combination of two chemotherapy drugs, cyclophosphamide and etoposide, can control advanced head and neck cancer in adults who have already tried standard treatment. 120 participants will receive either the drug combo or methotrexate for 6 month…

This phase 2 trial tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemoradiotherapy can help people with locally advanced esophageal cancer whose initial chemo-immunotherapy did not work. About 40 participants will receive the treatment…

This study tests a new combination of three drugs—becotatug vedotin, tislelizumab, and chemotherapy—for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The goal is to see if adding the targeted drug becotatug vedotin to standard im…

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests whether adding ficerafusp alfa to the immunotherapy nivolumab can shrink tumors better than nivolumab alone in people with advanced head and neck cancer that has stopped responding to platinum chemotherapy. About 131 adults aged 18-75 will take part. The goal is …

This study tests a new combination of drugs (QL1706 plus chemotherapy) as the first treatment for people with advanced or spreading esophageal cancer. About 50 adults who have not had prior treatment will receive the combo to see if it shrinks tumors and how long it keeps the can…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This study tests a combination of two drugs, SHR-1701 and liposomal irinotecan, in 33 adults with esophageal squamous cell carcinoma who have already received immunotherapy. The goal is to see if the combo can shrink tumors or stop them from growing. Participants will receive the…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This study tests a drug called sacituzumab tirumotecan in 20 people with advanced anal or rectal cancer that has spread or cannot be removed and has not responded to other treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive t…

This study tests whether giving the immunotherapy drug nivolumab before surgery can shrink tumors in people with advanced oral cancer. About 60 adults with resectable oral squamous cell carcinoma will receive nivolumab, then have surgery. Researchers will also look for biomarkers…

This study tests whether adding a targeted drug (cetuximab) to standard immunotherapy (pembrolizumab or finotonlimab) and chemotherapy helps people with advanced head and neck cancer live longer without their cancer growing. About 316 adults aged 18-70 with cancer that has spread…

This phase II trial is testing a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) for people with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this 3-week course is safe and effective at controlling the cancer while pos…

This study tests whether a combination of three drugs (camrelizumab, chemotherapy, and ivarmacitinib) given before surgery can help people with a type of esophageal cancer. The goal is to see if the treatment can eliminate or shrink the tumor enough to improve surgical outcomes. …

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This large Phase 3 trial tests a new drug called YL201 against standard chemotherapy in 440 people with advanced esophageal cancer that has worsened after initial treatment. YL201 is a targeted therapy designed to deliver chemo directly to cancer cells. The study aims to see if i…

This phase 2 trial tests two drugs, cemiplimab and cetuximab, given before surgery to people with advanced skin cancer that is hard to remove. The goal is to shrink the tumor enough to make surgery easier or even unnecessary. The study will enroll 27 participants across three sit…

This study tests a new combination of two drugs (becotatug vedotin and pucotenlimab) in 20 adults with advanced penile cancer that has spread and is EGFR-positive. Participants must have failed or be unable to tolerate chemotherapy. The goal is to see if the treatment can shrink …

This phase 2 trial tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery in 26 patients with locally advanced esophageal cancer. The goal is to see if this approach can completely eliminate cancer cells in the removed tis…

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This phase II trial is testing whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) and a targeted therapy (lenvatinib) to standard chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. The main goal is to…

This study tests whether a special scan (SPECT-CT) can show which side of the neck needs radiation in people with oropharyngeal cancer. Currently, both sides are treated to prevent hidden cancer spread, but this causes more side effects. The trial will enroll 128 patients to see …

This Phase 2 trial tests an experimental iron nanoparticle injection (CNSI-Fe) given directly into tumors along with standard radiotherapy. The goal is to see if the combination shrinks tumors better than radiation alone. The study will enroll 52 adults with head and neck cancer …

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This study tests whether a mixed reality system, similar to video game technology, can help surgeons remove oral cancer and rebuild the area more accurately. Thirty people with oral cancer will be split into three groups: one using mixed reality, one using a virtual surgical guid…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This study tests a low-cost approach to treat pre-cancerous and cancerous mouth lesions using a drug (5-ALA) that makes abnormal cells sensitive to light, followed by laser light delivered through a handheld device. The goal is to destroy these lesions without surgery. The trial …

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This study tests a personalized approach for people with advanced esophageal cancer that cannot be removed by surgery. Doctors will use MRI scans to guide a custom combination of chemotherapy, radiation, and immunotherapy. The goal is to see if this tailored treatment can help ke…

This study looks at people with advanced mouth or throat cancer who had chemotherapy and immunotherapy before surgery. After surgery, they will either get radiation, immunotherapy maintenance, or just be watched. The goal is to see which approach helps them live longer without th…

This study compares a non-invasive ultrasound treatment (HIFU) to standard observation for low-grade cervical lesions (LSIL/CIN1) in 180 pre-menopausal women. Most of these lesions go away on their own, but the trial aims to see if HIFU can speed up clearance of the lesion and th…

This phase 2 trial tests a combination of two immune-boosting drugs, L19IL2 and L19TNF, injected directly into skin tumors. It is for people with advanced cutaneous squamous cell carcinoma whose cancer has worsened despite or who cannot tolerate standard immunotherapy. Up to 92 p…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests whether adding fianlimab to the immunotherapy cemiplimab works better than cemiplimab alone at preventing cancer return in people with HPV-positive head and neck cancer who have signs of leftover cancer after initial treatment. About 68 adults will receive either…

This study tests whether a new combination of drugs (anlotinib hydrochloride plus benmelstobart) works better than the current standard treatment (toripalimab plus chemotherapy) for people with advanced esophageal cancer that has certain gene mutations. The trial will include 578…

This study tests whether adding the immunotherapy drug camrelizumab to either an EGFR antibody or chemotherapy helps people with advanced head and neck cancer live longer. About 246 adults with stage III or IV head and neck cancer will receive the treatment before and after surge…

This study tests a new approach for people with a certain type of throat cancer that is not low-risk. Participants first receive a combination of chemotherapy, immunotherapy, and a special type of radiation called lattice radiotherapy. Then, based on how much the tumor shrinks, t…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This study tests a drug called cosibelimab in 80 people with advanced skin cancer who also have a kidney transplant or a blood cancer. The drug works by helping the immune system attack cancer cells. Researchers will check if the tumors shrink and monitor for side effects.

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This phase 3 study tests a new drug called SYS6010 against standard chemotherapy in people with advanced esophageal cancer that has worsened after at least one prior treatment. About 436 participants will be randomly assigned to receive either SYS6010 or a standard chemo drug. Th…

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 108 people who have not had prior treatment will receive the combination. The study is not yet recr…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This phase 2 trial tests whether a single dose of the HPV vaccine (Gardasil-9) can reduce the infectivity of high-risk HPV in women aged 18-29 who already have the virus. Researchers will compare cervical samples from vaccinated and unvaccinated women at 6 months to see if vaccin…

This phase 3 trial will compare two surgical techniques for esophageal cancer: totally minimally invasive esophagectomy (TMIE) using only keyhole incisions, versus a hybrid approach that combines keyhole and open chest surgery. The study aims to see if TMIE reduces severe complic…

This Phase 3 trial tests whether giving a short course of targeted radiation (SBRT) followed by chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced oral or HPV-negative throat cancer. About 184 participants will be randomly assigned to rece…

This study tests whether a short course of radiation followed by three cycles of the immunotherapy drug serplulimab plus chemotherapy can help shrink esophageal tumors before surgery. It includes 22 adults with resectable esophageal squamous cell carcinoma. The goal is to see if …

This phase 2 trial tests whether giving a combination of the immunotherapy drug camrelizumab and two chemotherapy drugs (paclitaxel and carboplatin) before surgery can improve outcomes for people with advanced oral cavity or larynx cancer. Fifty participants will receive three cy…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This study tests a combination of a modified virus (H101) and a targeted chemotherapy procedure (TACE) in 20 adults with head and neck cancer that has returned or spread after at least two standard treatments. The goal is to shrink tumors and boost the immune system while limitin…

This study tests two drugs together—pucotenlimab and becotatug vedotin—for people with advanced cutaneous squamous cell carcinoma that cannot be removed by surgery. The goal is to see if the combination shrinks tumors better than current treatments. About 38 participants will rec…

This phase 2 trial tests whether the drug zipalertinib, given together with standard chemotherapy, can shrink tumors in people with a specific genetic type of non-small cell lung cancer before they have surgery. The study plans to enroll 16 adults with stage II to IIIB disease wh…

This study tests whether a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery can shrink or eliminate tumors in people with advanced head and neck cancer. About 30 adults aged 18-70 with stage III/IVA disease who have not had prior tr…

This study tests whether high intensity focused ultrasound (HIFU) works as well as standard cryotherapy (freezing) for treating low-risk basal cell carcinomas and Bowen's disease. About 294 adults with small skin cancers on their body (not face or hands) will be randomly assigned…

This phase 2 trial tests a drug called becotatug vedotin, given alone or with immune-boosting drugs (penpulimab or ivonescimab), before surgery for head and neck cancer. The goal is to see if these treatments can shrink tumors or even make them disappear completely. The study inv…

This phase II trial tests whether a special PET scan (FAPI-PET/CT) can help doctors choose the best treatment for people with resectable esophageal cancer. After two cycles of chemoimmunotherapy, the scan results will guide whether patients continue with more chemoimmunotherapy o…

This phase II trial tests a combination of three drugs (adebrelimab, nimotuzumab, and chemotherapy) given before surgery to 22 patients with resectable esophageal squamous cell carcinoma. The main goal is to see if the cancer disappears completely after treatment. If it works, th…

This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and docetaxel) is safe and tolerable as an initial treatment for people with advanced head and neck cancer. The study enrolls 26 adults whose tumors have a certain prote…

This phase II trial tests the immunotherapy drug sintilimab combined with radiotherapy in patients with resectable locally advanced head and neck cancer. Participants receive sintilimab before surgery, then again after surgery along with radiation. The study aims to see if this a…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with resectable locally advanced esophageal squamous cell carcinoma. About 390 participants will be randomly assigned to receive either torip…

This early-phase study tests a new type of radiation (lattice radiotherapy) given with chemotherapy and immunotherapy before surgery for oral cavity cancer. About 30 adults with advanced but removable tumors will receive different radiation doses to find the safest level. The goa…

This phase II trial tests whether adding pembrolizumab and lenvatinib to standard chemoradiation and brachytherapy can improve outcomes for adults with high-risk locally advanced cervical cancer. About 87 participants will receive the drug combination and be followed for two year…

This study tests whether adding chemotherapy to the immunotherapy drug toripalimab before surgery helps keep head and neck cancer from coming back. About 154 adults with advanced but operable cancer will get either toripalimab alone or with chemo for two cycles, then have surgery…

This study tests a new surgical technique for people with esophageal cancer. The method uses a special dye to check blood flow and wraps the surgical connection with a piece of belly tissue to prevent leaks. About 73 adults will receive this procedure to see if it lowers the risk…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This study tests a combination of three drugs (docetaxel, nimotuzumab, and pucotenlimab) in 30 adults with recurrent or metastatic head and neck cancer that has not responded to previous treatments. The goal is to see if this therapy can shrink tumors and improve survival. Partic…

This study tests a standardized care plan for esophageal fistula, a severe complication of advanced esophageal cancer where a hole forms between the esophagus and windpipe or chest. The plan includes sealing the hole with stents, antibiotics, nutrition support, and further cancer…

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This Phase 3 trial tests whether a new experimental drug called HB0025, combined with chemotherapy, works better than the standard immunotherapy pembrolizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer. About 480 participants who have not had p…

This study tests whether adding fianlimab to the standard cemiplimab plus chemotherapy can better shrink tumors in adults with advanced HPV-positive head and neck cancer. About 90 participants will receive either the two-drug or three-drug combination before radiation. The goal i…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This phase II trial tests whether surgically cutting the lingual nerve (which controls tongue sensation) can make chemoimmunotherapy work better for people with advanced tongue cancer. 69 adults with stage T3/T4 tongue cancer will receive the nerve cut along with two cycles of ti…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This study tests whether the drug toripalimab, given after surgery, can help prevent esophageal cancer from returning in patients at high risk of recurrence. About 435 adults who have already had chemotherapy and immunotherapy before surgery will either receive toripalimab or be …

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This study tests whether people with advanced head and neck cancer who respond to immunotherapy can safely have a smaller, less invasive surgery than usual. The goal is to preserve organ function and quality of life without lowering the chance of survival. About 356 participants …

This study tests whether adding an experimental drug called HLX07 to standard immunotherapy and chemotherapy helps people with advanced squamous non-small cell lung cancer. About 720 adults with stage 3B/4 disease will receive either the new combo or a placebo with standard treat…

This phase 2 trial tests a combination of two targeted drugs (sintilimab and nimotuzumab) plus chemotherapy for people with advanced head and neck cancer that hasn't spread. The goal is to see if this approach can shrink tumors enough to avoid removing the larynx (voice box). The…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This study tests a treatment called photodynamic therapy (PDT) for women with low-grade cervical precancer caused by HPV types 16 or 18. A photosensitizing cream is applied to the cervix, then activated with light to destroy abnormal cells. The trial will compare 225 women who re…

This study compares a light-activated gel treatment (ALA-PDT) to standard surgery (LEEP) for women with high-grade cervical precancer (HSIL/CIN2). About 560 women will receive either the gel plus red light therapy or surgery. The goal is to see if the gel treatment works as well …

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This study tests a new drug called QL1706 combined with chemotherapy for people with a type of esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough so that surgery can be done successfully. 24 adults with this cancer will receive the drug …

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This study is for people with esophageal cancer that did not shrink after initial treatment. It tests whether adding low-dose radiation to a combination of immunotherapy (toripalimab) and chemotherapy can improve outcomes. Participants will receive the treatment before surgery, a…

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This study tests a new combination of drugs for people with advanced or metastatic esophageal squamous cell carcinoma who have not had prior treatment. The experimental therapy includes SYS6010 (a targeted antibody-drug conjugate) plus SG001 (an immunotherapy), with or without st…

This study tests whether taking a short course of capecitabine pills before surgery can shrink tumors and improve outcomes for people with HPV-negative head and neck cancer. About 75 adults with stage III or IVa cancer will be randomly assigned to either standard care or capecita…

This Phase 3 trial tests whether the immunotherapy drug toripalimab can help prevent cancer from growing in people with advanced esophageal cancer who have already received chemotherapy and radiation. About 340 participants will be randomly assigned to receive toripalimab or just…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This study tests whether shrinking the radiation target area after chemotherapy can safely control stage IIb cervical cancer. Sixty participants will receive induction chemo followed by radiation that covers only the uterus, nearby tissues, and a small margin below the tumor. The…

This study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This study tests an immunotherapy called PDS0101 in 27 adults with both HIV and HPV 16. The goal is to see if it is safe and can strengthen the immune system's response against HPV, which can cause cancers like anal and cervical cancer. All participants will receive three doses o…

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This early-stage study tests a new drug called IPM514 in 36 people with advanced esophageal cancer that cannot be removed by surgery or has spread. The drug is given as a shot, and the main goals are to check safety and find the best dose. Researchers will also look for early sig…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This study tests a chemotherapy drug (TAS-102) combined with radiation in people aged 65-85 with advanced esophageal cancer. The goal is to find the safest dose and see if the combination helps control the cancer and improves survival. About 45 participants will take part across …

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This study tests whether giving two drugs—camrelizumab (an immunotherapy) and palbociclib (a targeted therapy)—before surgery can safely shrink tumors in people with esophageal cancer that can be removed. About 41 adults with resectable esophageal squamous cell carcinoma will rec…

This study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…

This pilot study will test whether a fish oil-enriched nutritional supplement, combined with weekly nutrition counseling, is feasible and safe for people with head and neck cancer undergoing chemoradiotherapy. Fifteen participants will start taking the supplement two weeks before…

This study tests whether extra dental care every three months for three years can prevent or reduce late side effects like dry mouth, cavities, and jaw stiffness in head and neck cancer survivors. 300 adults who completed radiation or chemoradiation will either get this extra sup…

This phase II trial tests whether a single low dose of radiation to all visible tumors can help immunotherapy work again in people with advanced esophageal cancer that has stopped responding to standard treatment. Thirty-two adults will receive the radiation and continue their or…

This early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…

This early-phase trial is testing a new approach for people with recurrent or metastatic head/neck cancer or esophageal cancer. The treatment combines a virus that delivers endostatin directly into tumors with an immunotherapy drug (PD-1 inhibitor). The goal is to see if the comb…

This study tests a new radioactive tracer called 64Cu-DOTA-ECL1i that aims to make PET scans more accurate for head and neck cancer. Researchers will enroll 90 adults with newly diagnosed or recurrent/metastatic head and neck squamous cell carcinoma. The goal is to see if this tr…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study aims to see if a simple blood test can find HPV-related oropharyngeal cancer early in men aged 50 and older who have no symptoms. Researchers will check blood for two markers of HPV and then follow up with those who test positive to find and treat any tumors. If succes…

This study will test artificial intelligence algorithms that analyze video from routine endoscopies of the head and neck. The AI will try to detect, classify (benign vs. malignant), and outline lesions, comparing its performance to doctors and lab results. About 283 adults with s…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This early-phase trial tests a fluorescent dye called ABY-029 that may help surgeons see head and neck cancer during surgery. About 24 adults with head and neck squamous cell carcinoma will receive a tiny amount of the dye before surgery. Researchers will check safety and find th…

This study will collect thousands of photos of mouth lesions from patients seen over 50 years at a French hospital. Experts will review each photo to confirm the diagnosis. Researchers will then use these images and patient data to train an AI system to automatically identify can…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This study tests whether a special dye, called indocyanine green, can help surgeons find cancer that has spread to nearby lymph nodes during esophageal cancer surgery. About 144 adults with esophageal cancer will take part. If the dye works well, it may allow doctors to remove fe…

This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…

This pilot study will test whether a fluorescent dye called indocyanine green (ICG), used with a special handheld camera, can find sentinel lymph nodes as well as the standard blue dye in early-stage vulvar cancer. Ten patients will receive both dyes during surgery, and doctors w…

This early-phase study will test a new radioactive tracer called [18F]-AraG in just 5 people with advanced head and neck cancer. Participants will receive two PET/CT scans (before and during standard chemoradiotherapy) to see if the tracer's uptake matches immune cell activity an…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This Phase 3 trial tests whether a daily imiquimod cream applied to the face for 12 weeks can prevent new basal cell carcinomas (BCC) in 1,630 veterans at high risk. Participants apply either the active cream or a placebo and are followed for up to 3 years with skin exams. The go…

This study tests whether a modified herbal mouthwash can prevent painful mouth sores caused by radiation therapy in people with head and neck cancer. About 156 participants will use either the herbal mouthwash or a placebo during their radiation treatment. The goal is to see if t…

This study looks at whether training pharmacy staff to better communicate about and manage the HPV vaccine can increase vaccination rates in children ages 9-17. About 1,900 participants, including pharmacy staff and parents, will be involved. The goal is to make it easier for fam…

This study tests whether the HPV vaccine can prevent the return of high-grade squamous intraepithelial lesions (HSIL) in people who have already been treated for them. About 984 adults aged 18–55 with HPV-related HSIL of the cervix, vulva, vagina, penis, or anus will receive eith…

This study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This trial compares early versus delayed acupuncture to reduce dry mouth caused by chemoradiation in head and neck cancer patients. Participants receive acupuncture either during chemoradiation or after, and their dry mouth symptoms are tracked for a year. The goal is to find the…

This study tests whether adding palliative care early — alongside standard chemoradiotherapy — can improve symptoms and quality of life for people with advanced head and neck cancer that cannot be surgically removed. Researchers will compare two groups: one receiving standard tre…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests whether a personalized, supervised exercise program done at home can improve physical function in people who have finished treatment for gastroesophageal cancer. About 20 survivors will receive tailored aerobic and resistance exercises via video calls. The goal i…

This study tests if a ketamine oral rinse can relieve pain from mouth sores (mucositis) caused by radiation therapy in head and neck cancer patients. About 62 adults receiving radiation will use the rinse and report their pain levels. The goal is to see if this simple rinse impro…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This study tests whether a common antibiotic ointment applied inside the nose can reduce severe mouth and throat pain caused by radiation therapy in head and neck cancer patients. About 126 participants will receive either the antibiotic or a placebo, and neither they nor their d…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study tests if a daily protein drink can lower the chance of severe mouth sores caused by radiation therapy in people with head and neck cancer. About 504 adults will either get the protein supplement or a placebo drink without protein during their radiation treatment. The g…

This study tests whether a new way of aiming radiation beams (non-coplanar) can reduce side effects like dry mouth and swallowing problems in people with head and neck cancer. About 70 adults with cancer of the mouth or throat will be randomly assigned to standard or new radiatio…

This study is for people with HPV-related oropharyngeal (throat) cancer, which often responds well to treatment. The goal is to see if lowering the radiation dose to certain areas can reduce side effects like dry mouth without hurting the chance of curing the cancer. About 132 pa…

This phase 3 trial tests whether a daily dose of sodium-copper-chlorophyllin, a chlorophyll derivative, can reduce long-term bladder and bowel side effects from radiation therapy in 316 women with locally advanced cervical cancer. Participants take the supplement for 3 months aft…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study tests whether rinsing with hydrogen water can reduce mouth inflammation and pain in people recovering from oral cancer surgery that used a free flap reconstruction. Thirty-six participants will use hydrogen water or plain water for oral care over 7 days. Researchers wi…

This study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…

This study tests whether using a laryngeal mask instead of a breathing tube during esophageal cancer surgery can reduce complications and speed up recovery. About 500 adults with resectable esophageal cancer will be randomly assigned to one of two anesthesia methods. The goal is …

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study will compare how quickly and how much THC enters the blood when people vape THC liquids versus smoking cannabis. Forty healthy adults who already use both products will try each method in a random order. Researchers will measure THC levels, side effects, and puffing be…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study looks at the care paths of 300 people with anal cancer to find out what causes delays in diagnosis. Researchers will track the time from first symptoms to diagnosis and check how screening and access to care affect outcomes. The goal is to improve awareness and help ca…

This study looks at how much pembrolizumab (an immunotherapy drug) remains in the blood after treatment ends and whether that affects how well chemotherapy works later. Researchers will follow 110 people with non-small cell lung cancer or head and neck cancer who have stopped pem…

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This study tests whether training healthcare providers to reduce stigma can increase the use of HIV and STI prevention services, like testing and preventive medications. It will involve 8 clinics in the Mississippi Delta and track changes in how often patients receive these servi…

This study tests better ways to screen and treat cervical cancer in women living with HIV in Kenya, who face a much higher risk. Researchers will use HPV self-testing, care navigators, and a mobile app to help more women get diagnosed and treated. The goal is to find strategies t…

This study will collect data from 10,000 people undergoing upper endoscopy to build an AI model that predicts the risk of developing stomach or esophageal cancer. Researchers will combine information from endoscopy images, tissue samples, genetics, and gut bacteria. Participants …

This study aims to see how nicotine changes eye movements in people who use e-cigarettes. Researchers will measure things like how fast eyes move and how well they follow objects, along with blood nicotine levels and self-reported feelings. The goal is to find a more objective wa…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study aims to understand the different cell types in oral cancer and pre-cancerous mouth lesions. Researchers will analyze tissue and blood samples from 150 participants to map gene activity and cell interactions. They will also test whether a simple brush sample can replace…

This study will check if certain immune cells, called precursor exhausted T cells, found in cancer-free lymph nodes can predict whether esophageal cancer completely disappears after immunotherapy. Researchers will study 88 patients before surgery to see if these cells are better …

This study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…

This study follows 120 people with laryngeal cancer to see how their quality of life, voice, swallowing, pain, and mood change before treatment and at 3, 6, and 12 months after. Researchers will use questionnaires to track these changes. The goal is to better understand recovery …

This observational study will enroll 158 adults with advanced or recurrent esophageal cancer who plan to receive PD-1 inhibitor immunotherapy. Researchers want to see if a high level of a specific immune cell type (precursor exhausted T cells, or Tpex) in cancer-free lymph nodes …

This study tests whether injecting two dyes around the tumor and into cancerous lymph nodes can help surgeons spot hidden cancer spread in head and neck cancer. Twenty adults with oral cavity or head and neck skin cancer will receive the dyes before surgery. The goal is to see if…

This study will follow 72 adults with early-stage gastroesophageal cancer to see how their physical function changes during chemotherapy. Participants will have their physical abilities measured at several points over six months. The goal is to understand which patients are at ri…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study will look at tumor samples from 12 people with esophageal cancer before and after they receive standard chemotherapy plus immunotherapy followed by surgery. Using advanced techniques like single-cell analysis, researchers aim to understand how the tumor environment cha…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study will collect tumor and blood samples from 120 people with head and neck squamous cell carcinoma. Researchers will create mouse models from the samples and analyze molecular markers to understand resistance to standard therapies. The goal is to find new treatment target…

This study looks at how surgery for a rare brain tumor called craniopharyngioma might change what foods people like, especially fatty and sugary ones. Researchers will compare food preferences of 346 adults who had this surgery with two other groups: people who had a different pi…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study aims to see if changes in certain immune cells in the blood can predict how well advanced lung cancer patients respond to a combination of chemotherapy and immunotherapy. About 80 adults with stage IIIB or IV non-small cell lung cancer will give blood samples before an…

This study looks back at 238 patients with a common skin cancer called squamous cell carcinoma. Researchers will compare special skin photos (dermoscopic images) with lab results from removed tumors. The goal is to see if certain features in the photos can tell how deep the cance…

This study looks at whether using a high-frequency ultrasound before surgery for common skin cancers on the head and neck can help surgeons remove the entire tumor the first time. About 400 adults with basal or squamous cell skin cancer will be in the study. Some will get the sta…

This pilot study will test whether trained community health navigators can help head and neck cancer patients get diagnosed and treated faster after an emergency room visit. The navigators will call or text patients to help with barriers like transportation, insurance, or housing…

This study will follow 750 adults in France who undergo endoscopic submucosal dissection (ESD) for early esophageal cancer or precancerous Barrett's esophagus. Researchers will track how well the procedure removes the cancer, how often it comes back, and whether additional treatm…

This study aims to better predict how head and neck cancer responds to chemoradiotherapy. Researchers will use MRI, PET/CT scans, and blood/tumor DNA tests from 152 patients to build a combined prediction model. The goal is to identify which patients have a complete response with…

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study aims to develop an AI system that helps doctors choose the best treatment for esophageal cancer. Researchers will collect data from 7,000 patients, including medical images and tissue samples, to train a computer model that predicts how well a patient will respond to t…

This study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…

This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…

This study will follow 255 people with esophageal cancer to understand how the disease changes over time. Researchers will use advanced tests like genetic analysis, imaging, and immune profiling. The goal is to improve how doctors predict cancer progression and response to treatm…